BMEA - NASDAQ
Biomea Fusion, Inc.
$1.38
+6.2%Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
At a Glance
Live SnapshotBiomea Fusion, Inc. Management Team
Dr. Stephan Morris M.D.
Chief Development Officer
Dr. Juan Pablo Frias M.D.
Chief Medical Officer
Compensation
$492,250
Ms. Naomi Cretcher
Chief People Officer
Mr. Heow Tan
Chief Technology & Quality Officer
Mr. Ramses M. Erdtmann
Co-Founder, President, Chief Operating Officer & Director
Compensation
$489,604
Dr. Thorsten Kirschberg Ph.D.
Executive Vice President of Chemistry
Mr. Ravi Upasani Ph.D.
Executive Vice President of Intellectual Property
Dr. Michael J. M. Hitchcock Ph.D.
Interim Chief Executive Officer & Director
Compensation
$56,500
Caroline Perez- Dupont J.D.
Senior Vice President of Contracts
Biomea Fusion, Inc. Insider Positioning
During the last 12 months, insiders have purchased $4.43M worth of BMEA shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
30.0K
43.00K
0
0.00
+43K
+$43K
6-9 Months
150.0K
153.73K
0
0.00
+154K
+$154K
9-12 Months
2.5M
4.23M
0
0.00
+4.2M
+$4.23M
Top Buyers
Erdtmann Rainer M
Director, Officer: See Remarks
$2.01M
Hitchcock Michael J.M.
Director, Officer: Interim Ceo
$1.50M
Ray Sumita
Director
$230K
Chen Bihua
Director, 10 Percent Owner:
$230K
Aguiar Eric
Director
$230K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $4.43M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
BMEA - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | June 10, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | June 11, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 12, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 14, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 22, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.